STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #393 by analyst upside · 2026-06-27
IMRX
Immuneering Corporation
Healthcare · Market Cap $308M · P/E 0x
ANALYST PRICE TARGET
+257.1%
implied upside to consensus target
Current Price $4.76
Consensus Target $17.0
Bull Target $30.0
Bear Target $11.0
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
0
Sell
0
52-Week Low $2.9
52-Week High $10.08
YTD Return -28.1%
FUNDAMENTALS
Market Cap $308M
P/E Ratio (TTM) N/A
Forward P/E -3.6x
EPS (TTM) $-1.06
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.9
52-Week High $10.08
Current Price $4.76
Bear Target $11.0
Bull Target $30.0
● Now $4.76 ● Target $17.0
TRADING DATA
Avg Volume 1.3M
YTD Return -28.1%
Analyst Count 6
Consensus Buy
Upside to Target +257.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Immuneering Corporation (IMRX) is currently trading at $4.76 with a Wall Street consensus price target of $17.0, implying potential upside of 257.1% over the next 12 months. 6 analysts currently cover IMRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $11.0.

IMRX operates in the Healthcare sector with a market capitalisation of $308M. The stock is down 28.1% year-to-date and is currently trading near the lower end of its 52-week range of $2.9 – $10.08.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IMRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-05-19 33% win rate (6 calls)
Needham reit
Buy → Buy 2026-03-09 20% win rate (5 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-11-13 33% win rate (6 calls)
Leerink Partners ● Initiated
Outperform 2025-10-31 29% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-30 31% win rate (48 calls)
Chardan Capital — Reiterated
Buy → Buy 2025-09-26 33% win rate (6 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-09-25 14% win rate (7 calls)
Needham — Reiterated
Buy → Buy 2025-09-15 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →